Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16693739 | 1.00 | EPHA2 (0.43) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL18896596 | 1.00 | EPHA2 (0.43) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL16692104 | 0.89 | EPHA2 (0.45) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL16692114 | 0.89 | EPHA2 (0.45) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL619933 | 0.87 | EPHA2 (0.44) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL620135 | 0.87 | EPHA2 (0.44) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL619934 | 0.87 | EPHA2 (0.44) | EPHA2ERBB2EPHB4P2RX3P2RX2 | |
| SCHEMBL29068409 | 0.87 | CHEK1 (0.39) | LRRK2 | |
| SCHEMBL15392128 | 0.87 | CHEK1 (0.39) | LRRK2 | |
| SCHEMBL30186246 | 0.86 | ENPP2 (0.38) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115443271-A | Synthetic method of CHK1 inhibitor | 塞拉肿瘤学股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-10259806-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20180022739-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022739-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CHEK1, CHEK2, BUB1B | EPHA2 3391/4885ERBB2 671/4885EPHB4 3955/4885 |
| US-10259806-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CHEK1, CHEK2, CDK1 | EPHA2 3385/4885ERBB2 723/4885EPHB4 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.